Docetaxel intratumoural (LIDDS/Uppsala University)

多西他赛瘤内注射制剂 (LIDDS/Uppsala University)

Report date: 2025/04/24 17:01:15

Base Information

Drug NameDocetaxel intratumoural (LIDDS/Uppsala University)
Drug Alias NameNanodotaxNanoZolid-docetaxelNZ-DTXNZ-DTX Depot
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin depolymerization inhibitors
TargetsTubulin
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEuropeSwedenDenmark
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLidds Ab
China Registration ClassN/A

Develop Information

Active CompaniesLidds AbUppsala University
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A